Table V.
Change from baseline to last available measurements of vital signs and blood measurements
| Percentage change, % |
|||
|---|---|---|---|
| Discontinuation of RAAS inhibitor (N = 21) | Continuation of RAAS inhibitor (N = 25) | Group difference P-value* | |
| Vital signs | |||
| Heart rate, BPM | -10.1 (-13.1, 6.3) | 0.0 (-10.3, 15.3) | .486 |
| Resting systolic blood pressure, mmHg | -2.5 (-13.0, 11.5) | -0.8 (-10.2, 5.9) | .686 |
| Resting diastolic blood pressure, mmHg | 10.8 (-8.8, 17.1) | 7.3 (0, 18.3) | .942 |
| Resting respiratory rate, respirations/minute | 0.0 (-10.0, 0.0) | 0.0 (0.0, 2.8) | .277 |
| Biomarkers | |||
| Serum Hemoglobin, mmol/L | -3.1 (-6.5, 3.3) | -0.9 (-4.8, 2.5) | .769 |
| Serum Sodium, mmol/L | 0.0 (-1.4, 2.2) | 0.7 (-1.4, 1.5) | .517 |
| Serum Potassium, mmol/L | -4.1 (-7.7, 12.8) | 8.3 (2.3, 16.3) | .065 |
| Blood Urea Nitrogen, mmol/L | 23.8 (8.9, 51.8) | 18.4 (-11.2, 54.0) | .728 |
| Serum Glucose, mmol/L | -1.7 (-39.0, 24.1) | 1.9 (-16.7, 24.4) | .435 |
| C-reactive protein, mg/L | -40.7 (-70.1, 17.7) | -50.0 (-71.3, 6.7) | .608 |
| Lymphocyte count x 109 | 38.1 (-11.5, 80.0) | 4.7 (-14.2, 62.0) | .925 |
| High-sensitivity Troponin I† | -20.3 (-48.7, 31.3) | -14.1 (-35.6, 16.1) | .469 |
| Natriuretic Peptides BNP, pg/mL | 16.7 (4.9, 35.0) | -27.5 (-40.0, 38.9) | .024 |
| eGFR, mL/min/1.73 m2 | -1.5 (-12.4, 12.3) | 0.0 (-6.5, 10.8) | .746 |
BNP, brain natriuretic peptide; BPM, beats per minute; eGFR, estimated glomerular filtration rate; RAAS, renin-angiotensin aldosterone system.
Data are reported as median with interquartile range (Q1, Q3).
⁎
Group difference was evaluated on log transformed data.